# Akari Therapeutics Akari Therapeutics is an other based in United Kingdom. ## Overview - **Organization type:** other - **Headquarters:** United Kingdom - **Region:** Europe - **Assets under management:** Undisclosed - **Website:** akaritx.com ## Regulatory record - **Reports private funds:** No ## About Akari Therapeutics is a clinical-stage biotechnology company incorporated in the United Kingdom with American depositary shares trading on the Nasdaq. The firm advanced a C5 complement inhibitor, nomacopan, as its core asset, initially targeting paroxysmal nocturnal hemoglobinuria before pivoting toward pediatric thrombotic microangiopathy associated with hematopoietic stem-cell transplant—a rare condition with no approved therapies. The company has historically maintained a lean operating model, outsourcing much of its manufacturing and clinical operations while concentrating internal resources on regulatory strategy and trial design. Nomacopan operates as both a C5 complement inhibitor and a leukotriene B4 antagonist, a dual mechanism Akari believes differentiates it from pure-play complement drugs. The current strategy centers on enrollment and data from a single pivotal Phase 3 pediatric trial. The firm has explored other indications including bullous pemphigoid and atopic keratoconjunctivitis, but publicly disclosed priorities have tightened around the pediatric HSCT-TMA program. In late 2022, Akari announced a merger with Peak Bio, which brought additional pipeline assets and a public listing vehicle; the combined entity trades under the Akari name. Akari does not disclose a large internal research workforce or extensive laboratory infrastructure. The firm's historical regulatory filings describe a controlled burn-rate strategy, relying on periodic public-market financings and partnership discussions to fund operations. The merger with Peak Bio in November 2023 extended cash runway and introduced co-development interests. Akari's board has historically included cross-border biotechnology and rare-disease veterans who bring expertise in navigating European and U.S. regulatory pathways for orphan-designated products. Unlike discovery-stage biotechs that maintain broad-platform science, Akari is structured around a single pivotal clinical outcome. The company's value proposition is binary—regulatory approval for nomacopan's lead indication or strategic sale of the asset—mirroring a model common among European public biotechs with no internal commercial infrastructure. Governance includes a board-level focus on capital allocation toward the Phase 3 readout expected in the 2025–2026 window. ## Questions ### What is Akari Therapeutics' lead asset and its current development stage? Nomacopan is a recombinant small protein that inhibits both C5 complement and leukotriene B4. The firm is running a single pivotal Phase 3 clinical trial evaluating nomacopan in pediatric patients with hematopoietic stem-cell transplant-related thrombotic microangiopathy, a rare and severe complication with no approved drug therapy. ### Who leads Akari Therapeutics and what is her background? Rachelle Jacques was appointed CEO in 2023. She previously served in senior commercial and portfolio-strategy roles at Horizon Therapeutics and other rare-disease companies, bringing specific expertise in drug launches for ultra-orphan indications. ### How did the merger with Peak Bio affect Akari's structure? The all-stock merger closed in November 2023, with Peak Bio becoming a wholly owned subsidiary. The combined company retained the Akari Therapeutics name and Nasdaq ticker while gaining Peak Bio's pipeline assets, including a preclinical antibody-drug-conjugate program and access to Peak Bio's public-company infrastructure. ### Does Akari Therapeutics have any revenue or commercial products? No. Akari is a clinical-stage company without approved products or recurring revenue. Operations are funded through public-market equity offerings and the occasional strategic partnership, with cash runway tied directly to clinical-trial milestones. ## Related profiles - [AIRWA](https://altss.com/profile/airwa-inc) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/akari-therapeutics-plc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology